The phenylketonuria market size is projected to grow at a compound annual growth rate of 10.95% over the forecast period of 2022 to 2029. Data Bridge Market Research report on phenylketonuria (PKU) treatment market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecasted period while providing their impacts on the market’s growth.
Phenylketonuria (PKU) is basically a rare inherited genetic disorder which increases the levels of phenylalanine (an amino acid) in the blood. Phenylalanine is an amino acid which is comprised of proteins obtained from food and diet. Phenylalanine hydroxylase enzyme converts phenylalanine in to tyrosine amino acid in human body. The excess of phenylalanine in the blood can cause psychiatric disorders, seizures and many other untreated disorders.
Sample copy of report- https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-phenylketonuria-market
Phenylketonuria is an inborn error of metabolism that is detectable during the first days of life via routine newborn screening. Phenylketonuria is characterized by the absence or deficiency of an enzyme called phenylalanine hydroxylase (PAH), responsible for processing the amino acid phenylalanine. Amino acids are the chemical building blocks of proteins and are essential for proper growth and development. With normal PAH activity, phenylalanine is converted to another amino acid, tyrosine. However, when PAH absent or deficient, phenylalanine accumulates and is toxic to the brain. Without treatment, most people with Phenylketonuria would develop a severe intellectual disability. To prevent intellectual disability, treatment consists of a carefully controlled, phenylalanine-restricted diet beginning during the first days or weeks of life.
Full asceses of report- https://www.databridgemarketresearch.com/reports/global-phenylketonuria-market
Major toc of the report
- Chapter One: Introduction
- Chapter Two: Market Segmentation
- Chapter Three: Market Overview
- Chapter Four: Executive Summary
- Chapter Five: Premium Insights
TOC Details: https://www.databridgemarketresearch.com/toc/?dbmr=global-phenylketonuria-market
The major players covered in the phenylketonuria market report are DAIICHI SANKYO COMPANY, LIMITED, Ajinomoto Cambrooke, Inc., American Gene Technologies, Ultragenyx Pharmaceutical, Nutricia, Homology Medicines, Inc., Reckitt Benckiser Group plc, Abbott, Travere Therapeutics, Inc., Synlogic, Promin., SOM BIOTECH, S.L. Healthcare, Synthetic Biologics, Inc., Nestlé, Codexis, BioMarin, Erytech Pharma., Censa Pharmaceutical Inc., Rubius Therapeutics, Inc., among other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately.
Q1. Which is the most lucrative country for phenylketonuria treatment?
The U.S., at present, holds the maximum market share and leads the global phenylketonuria treatment market. The U.S. is expected to experience significant demand for phenylketonuria treatment over the entire forecast period.
Q2. Which ingredient holds a significant share in the market?
Essential and non-essential amino acids hold the highest market share of one-third. These continue to dominate the market based on protein ingredient as well as finished product.
Q3. Which form of PKU ingredient is expected to dominate phenylketonuria treatment?
Based on protein ingredient, the powder blend form accounted for the highest share, while based on finished product, powder and the granule forms accounted for high shares in the phenylketonuria treatment market.
Q4. Which are the leading companies in phenylketonuria treatment market?
Some of the prominent companies offering phenylketonuria treatment are for protein ingredients - Arla Foods Ingredients Group P/S, Archer Daniels Midland Company, BASF SE, Chr. Hansen, Cargill, Incorporated, Seidler Chemical Co, Inc. Additionally for the finish products for PKU treatment the manufacturers include- Nestlé S.A. (Vitaflo International), Reckitt Benckiser Group plc. (Mead Johnson Company, LLC.), Abbott Laboratories, APR Applied Pharma Research S. A., Ajinomoto Co., Inc., VitafriendsPKU, Pristine Organics Pvt. Ltd., and others.
Q5. What are the restraining factors phenylketonuria treatment?
Challenges associated can be the high cost of PKU treatment, inconsistent reimbursement policies, and lack of treatment regimen compliance.
Profound Questions Answered in this Report:
- What is the growth rate of various stages in the value chain of the industry?
- Which region has the highest growth rate and size of the emerging market by value in 2021?
- Who are the competitive players inpoint of care (POC) lipid test market?
- Which region has the largest share and degree of competition in the industry?
- What is the CAGR of the market during the forecast period 2022 to 2029?
- Which region is expected to hold the highest market share for the market?
- What is the main driver of the point of care (POC) lipid test market?
- What is sales volume, revenue, and price analysis of top players of the market?
- What are the market opportunities and threats faced by the vendors in the industry?
- What has been the impact of COVID-19 on the point of care (POC) lipid test market?
Browse Related Reports
About Us:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market
Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email: Sopan.gedam@databridgemarketresearch.com
